
Leo Pharma has paid the second milestone payment to the Belgian biotech company Argenx.
In May 2015, the two companies entered into a research collaboration to develop the antibody-based candidate drug ARGX-112 and Argenx has just finished the preclinical work with this drug.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app